Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -1.79%48 Operating Margin % is -892.72% as of Dec. 2025. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.90 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, OncoSil Medical ranks worse than 94.49% on this metric.
The historical rank and industry rank for OncoSil Medical's Operating Margin % or its related term are showing as below:
ASX:OSL'
s Operating Margin % Range Over the Past 10 Years
Min: -5545.54 Med: -3458.97 Max: -1021.07
Current: -1021.07
ASX:OSL's Operating Margin % is ranked worse than 94.49% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 3.17
vs ASX:OSL: -1021.07
OncoSil Medical's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
OncoSil Medical (ASX:OSL) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
OncoSil Medical Operating Margin % Related Terms
OncoSil Medical Operating Margin % Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:OSL vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, OncoSil Medical's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Operating Margin % distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
OncoSil Medical's Operating Margin % for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical (ASX:OSL) has a Operating Margin % of -892.72% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on OncoSil Medical and its competitors. According to the industry distribution chart, OncoSil Medical ranks #772 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is OncoSil Medical's Operating Margin % too high?
OncoSil Medical's current Operating Margin % is -892.72%. Based on the distribution chart, OncoSil Medical ranks #772 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #772 out of 817 companies for Operating Margin %. This places OncoSil Medical in the lower half of its industry. The industry median Operating Margin % is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.17, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on OncoSil Medical and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Operating Margin % is -892.72%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.90, compared to a current price of A$1.38 — trading 52.6% below its estimated fair value. The current Operating Margin % is -892.72%. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Operating Margin % is -892.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.38 is trading 52.6% below its estimated GF Value™ of A$2.90.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Operating Margin %: -892.72%
GF Value™: A$2.90 vs. price of A$1.38 (52.6% below fair value)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:OSL
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
